KMR Group To Assess Clinical Trial Cost - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
KMR Group To Assess Clinical Trial Cost

Source: Applied Clinical Trials

KMR Group is initiating a benchmarking study to assess clinical trial cost. Utilizing both its expertise in clinical trial and site performance analysis, and years of portfolio level cost evaluation for drug development, the study will examine costs from recent global clinical trials. The study will assess both the resource and expense side of running a clinical trial. The expense side will provide further insight into non-resource clinical trial costs, including the breakdown of outsourcing costs and investigator costs. Results are expected to be available in the first part of next year.

Read the full release here.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here